By otakuyassine3@gmail.com 
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $40.40.
Several brokerages have weighed in on DNLI. Bank of America upped their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group boosted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald downgraded shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th.
Get Our Latest Stock Analysis on DNLI
Denali Therapeutics Price Performance
Denali Therapeutics stock opened at $21.45 on Monday. The business has a 50 day simple moving average of $25.82 and a 200 day simple moving average of $24.93. The company has a market capitalization of $3.09 billion, a PE ratio of -7.77 and a beta of 1.35. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.33.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the prior year, the company earned ($0.72) earnings per share. Equities analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.
Insider Transactions at Denali Therapeutics
In other news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. The trade was a 50.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 15,558 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the sale, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,578 shares of company stock worth $2,474,440 in the last quarter. 7.90% of the stock is owned by company insiders.
Institutional Investors Weigh In On Denali Therapeutics
Several large investors have recently bought and sold shares of the company. FMR LLC grew its holdings in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after acquiring an additional 1,451,770 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Denali Therapeutics during the second quarter worth about $24,454,000. Wellington Management Group LLP grew its position in shares of Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares during the period. Finally, Integral Health Asset Management LLC bought a new stake in Denali Therapeutics during the 2nd quarter worth approximately $7,546,000. Institutional investors own 92.92% of the company’s stock.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More
Receive News & Ratings for Denali Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Denali Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.